検索結果

iod required for regulatory approval, resulting in early approval and launch. CRAO, the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...

ound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...

iod required for regulatory approval, resulting in early approval and launch. CRAO, the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...